|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2012-01-01 |
Prospective Non Interventional Phase IV Multi-centre Canadian Study on the Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion Under 63 Days Gestation
National multi-center non interventional study aiming at investigating the effectiveness and safety of the combination mifepristone-misoprostol prescribed in Canada to women for medical termination of pregnancy at or before 63 days gestational age through a multi-center prospective non interventional study design.
100 项与 Linepharma International Ltd. 相关的临床结果
0 项与 Linepharma International Ltd. 相关的专利(医药)
100 项与 Linepharma International Ltd. 相关的药物交易
100 项与 Linepharma International Ltd. 相关的转化医学